The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial
Open accessAbstract
Importance: Mutations of the glucocerebrosidase gene, GBA1 (OMIM 606463), are the most important risk factor for Parkinson disease (PD). In vitro and in vivo studies have reported that ambroxol increases β-glucocerebrosidase (GCase) enzyme activity and reduces α-synuclein levels. These observations support a potential role for ambroxol therapy in modifying a relevant pathogenetic pathway in PD. Objective: To assess safety, tolerability, cerebrospinal fluid (CSF) penetration, and target engagement of ambroxol therapy with GCase in patients with PD with and without GBA1 mutations. Interventions: An escalating dose of oral ambroxol to 1.26 g per day. Design, Setting, and Participants: This single-center open-label noncontrolled clinical trial was conducted between January 11, 2017, and April 25, 2018, at the Leonard Wolfson Experimental Neuroscience Centre, a dedicated clinical research facility and part of the University College London Queen Square Institute of Neurology in London, United Kingdom. Participants were recruited from established databases at the Royal Free London Hospital and National Hospital for Neurology and Neurosurgery in London. Twenty-four patients with moderate PD were evaluated for eligibility, and 23 entered the study. Of those, 18 patients completed the study; 1 patient was excluded (failed lumbar puncture), and 4 patients withdrew (predominantly lumbar puncture-related complications). All data analyses were performed from November 1 to December 14, 2018. Main Outcomes and Measures: Primary outcomes at 186 days were the detection of ambroxol in the CSF and a change in CSF GCase activity. Results: Of the 18 participants (15 men [83.3%]; mean [SD] age, 60.2 [9.7] years) who completed the study, 17 (8 with GBA1 mutations and 9 without GBA1 mutations) were included in the primary analysis. Between days 0 and 186, a 156-ng/mL increase in the level of ambroxol in CSF (lower 95% confidence limit, 129 ng/mL; P < .001) was observed. The CSF GCase activity decreased by 19% (0.059 nmol/mL per hour; 95% CI, -0.115 to -0.002; P = .04). The ambroxol therapy was well tolerated, with no serious adverse events. An increase of 50 pg/mL (13%) in the CSF α-synuclein concentration (95% CI, 14-87; P = .01) and an increase of 88 ng/mol (35%) in the CSF GCase protein levels (95% CI, 40-137; P = .002) were observed. Mean (SD) scores on part 3 of the Movement Disorders Society Unified Parkinson Disease Rating Scale decreased (ie, improved) by 6.8 (7.1) points (95% CI, -10.4 to -3.1; P = .001). These changes were observed in patients with and without GBA1 mutations. Conclusions and Relevance: The study results suggest that ambroxol therapy was safe and well tolerated; CSF penetration and target engagement of ambroxol were achieved, and CSF α-synuclein levels were increased. Placebo-controlled clinical trials are needed to examine whether ambroxol therapy is associated with changes in the natural progression of PD. Trial Registration: ClinicalTrials.gov identifier: NCT02941822; EudraCT identifier: 2015-002571-24.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
Self-citationReduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Maegawa, G. H. B., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012393 · Cited by 332
McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., et al. (2014) · Brain · doi:10.1093/brain/awu020 · Cited by 321
Self-citationAlpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Xilouri, M., Brekk, O. R., & Stefanis, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8341-2 · Cited by 299
Mazzulli, J. R., Zunke, F., Tsunemi, T., Toker, N. J., Jeon, S., Burbulla, L. F., Patnaik, S., Sidransky, E., Marugan, J. J., Sue, C. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0628-16.2016 · Cited by 273
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Sardi, S. P., Clarke, J., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 251
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaïti, B., Bonaïti-Pellié, C., & Brice, A. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f476 · Cited by 238
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
Narita, A., Shirai, K., Itamura, S., Matsuda, A., Ishihara, A., Matsushita, K., Fukuda, C., Kubota, N., Takayama, R., Shigematsu, H., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.292 · Cited by 206
Ambroxol effects in glucocerebrosidase and α‐synuclein transgenic mice
Migdalska‐Richards, A., Daly, L., Bezard, E., & Schapira, A. H. V. (2016) · Annals of Neurology · doi:10.1002/ana.24790 · Cited by 204
Self-citationYap, T. L., Gruschus, J. M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., & Lee, J. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237859 · Cited by 174
Rocha, E. M., Smith, G. A., Park, E. Y. H., Cao, H., Graham, A.-R., Brown, E., McLean, J. R., Hayes, M. A., Beagan, J. A., Izen, S. C., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6307 · Cited by 162
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase
Bendikov-Bar, I., Maor, G., Filocamo, M., et al. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.10.007 · Cited by 147
Grabowski, G. A., Zimran, A., & Ida, H. (2015) · American Journal of Hematology · doi:10.1002/ajh.24063 · Cited by 146
Accuracy of clinical diagnosis of idiopathic Parkinson's disease.
Rajput, D. R. P. S. (1993) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.8.938 · Cited by 144
Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
Migdalska‐Richards, A., Ko, W. K. D., Li, Q., Bézard, E., & Schapira, A. H. V. (2017) · Synapse · doi:10.1002/syn.21967 · Cited by 122
Self-citationAge-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling
Rana, H. Q., Balwani, M., Bier, L., & Alcalay, R. N. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.107 · Cited by 118
Unfolded protein response in Gaucher disease: from human to Drosophila
Maor, G., Rencus‐Lazar, S., Filocamo, M., Steller, H., Segal, D., & Horowitz, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-140 · Cited by 114
Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
Magalhães, J., Gegg, M. E., Migdalska‐Richards, A., & Schapira, A. H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-19479-8 · Cited by 95
Self-citationZhang, Y., Li, S., Sun, Q., Zhou, X. C., Pan, H., Guo, J., & Tang, B. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00043 · Cited by 89
Yang, S., Beavan, M. S., Chau, K., Taanman, J., & Schapira, A. H. V. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.011 · Cited by 73
Self-citationCSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients
Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., Biticchi, B., Colona, V. L., Mercuri, N. B., Bernardini, S., & Pisani, A. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.018 · Cited by 46
Neurological effects of glucocerebrosidase gene mutations
Mullin, S., Hughes, D. A., Mehta, A. B., & Schapira, A. H. V. (2018) · European Journal of Neurology · doi:10.1111/ene.13837 · Cited by 40
Self-citationBabajani, G., Tropak, M. B., Mahuran, D. J., & Kermode, A. R. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.04.018 · Cited by 38
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Self-citationGBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
Self-citationGut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics
Tan, A. H., Chong, C. W., Lim, S., Yap, I. K. S., Teh, C. S. J., Loke, M. F., Song, S., Tan, J. Y., Ang, B. H., Tan, Y. Q., et al. (2021) · Annals of Neurology · doi:10.1002/ana.25982 · Cited by 196
Metadata
- Authors
- Mullin, S., Smith, L., Lee, K., D’Souza, G., Woodgate, P., Elflein, J., Hällqvist, J., Toffoli, M., Streeter, A., Hosking, J., Heywood, W. E., Khengar, R., Campbell, P., Hehir, J., Cable, S., Mills, K., Zetterberg, H., Limousin, P., Libri, V., Foltynie, T., & Schapira, A. H. V.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-04-01
- Volume
- 77
- Issue
- 4
- Pages
- 427
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2998953100
- Cited by
- 356
- References
- 29
- FWCI
- 25.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.